Disease · MONDO_0001106

kidney failure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kidney failure. Diseases, record MONDO_0001106. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001106

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kidney failure; Open Targets
Open Targets ID: MONDO_0001106; Open Targets
Other names: Renal failure in adulthood, failure, renal, renal failure, renal failure syndrome, renal insufficiency; Open Targets
Disease Ontology: DOID:1074; Disease Ontology
MeSH: D051437; MeSH
NCI Thesaurus: C4376; NCI Thesaurus
Highest stage of its drugs: Approval, for 8 of its 80 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs80

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TERLIPRESSIN	CHEMBL2135460	Protein	Approval	FDA	2	1	1	Drugs and targets
CAPTOPRIL	CHEMBL1560	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
DOPAMINE HYDROCHLORIDE	CHEMBL1557	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
BENAZEPRIL HYDROCHLORIDE	CHEMBL1694	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CALCIUM ACETATE	CHEMBL1200800	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MANNITOL	CHEMBL689	Small molecule	Approval	TTD	1	0	0	Drugs and targets
METOCLOPRAMIDE HYDROCHLORIDE	CHEMBL1200940	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
QUINAPRIL HYDROCHLORIDE	CHEMBL1201011	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 80

See all 80 drugs

Targets149

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACE	Angiotensin-converting enzyme	5	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
ADRB1	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
SERPINC1	Antithrombin-III	4	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	3	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ADORA1	Adenosine receptor A1	2	Adenosine A1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/134	Drugs and targets
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
ADRB2	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor beta antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets

1 to 10 of 149

See all 149 targets

Trials69

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01885559	HALT Progression of Polycystic Kidney Disease Study B	Phase 3	486	2015-03-10	Kidney, Polycystic	LISINOPRIL ANHYDROUS, TELMISARTAN	Its record names the disease	ClinicalTrials.gov
NCT03762850	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Phase 3	406	2024-07-03	Immunoglobulin A Nephropathy	DAPAGLIFLOZIN, SPARSENTAN	Its record names the disease	ClinicalTrials.gov
NCT01143246	A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin	Phase 3	196	2022-11-29	Hepatorenal Syndrome	TERLIPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT00533442	Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients	Phase 2	170	2017-07-12	Type 1 Diabetes	MYCOPHENOLATE MOFETIL, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00446459	Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.	Phase 2	45	2010-03-30	Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal	MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT04622709	Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis	Phase 2	39	2022-06-13	Chronic Kidney Disease Requiring Chronic Dialysis	FUROSEMIDE	Its record names the disease	ClinicalTrials.gov
NCT02424851	Optimising Renal Outcome in Myeloma Renal Failure	Phase 2	31	2022-01-27	Multiple Myeloma, Chronic Kidney Disease	BENDAMUSTINE, BORTEZOMIB, DEXAMETHASONE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02022748	Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects	Phase 1	27	2017-09-29	Kidney Failure, Chronic	TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT01936519	Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.	Not applicable	24	2021-01-12	Immunosuppression, Renal Failure	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04152200	A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1	Phase 3	21	2022-07-12	Primary Hyperoxaluria Type 1, Primary Hyperoxaluria	LUMASIRAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 69

See all 69 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ACE-I + Placebo vs ACE-I + ARB: serious adverse events	88 of 242	88 of 244	486	NCT01885559	Trial comparisons
ACE-I + Placebo vs ACE-I + ARB: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.	116 of 242	115 of 243	485	NCT01885559	Trial comparisons
Sparsentan vs Irbesartan: deaths from any cause	0 of 202	1 of 202	404	NCT03762850	Trial comparisons
Sparsentan vs Irbesartan: serious adverse events	75 of 202	71 of 202	404	NCT03762850	Trial comparisons
Terlipressin vs Placebo: deaths from any cause	41 of 97	45 of 99	196	NCT01143246	Trial comparisons
Terlipressin vs Placebo: serious adverse events	62 of 93	59 of 95	188	NCT01143246	Trial comparisons
Tacrolimus Plus MMF Plus Steroids vs Tacrolimus Plus Rapamycin Plus Steroids: deaths from any cause	16 of 86	15 of 84	170	NCT00533442	Trial comparisons
Tacrolimus Plus MMF Plus Steroids vs Tacrolimus Plus Rapamycin Plus Steroids: serious adverse events	40 of 86	38 of 84	170	NCT00533442	Trial comparisons
Arm A (BBD) vs Arm B (BTD): deaths from any cause	7 of 16	2 of 15	31	NCT02424851	Trial comparisons
Arm A (BBD) vs Arm B (BTD): Overall Survival	9 of 16	13 of 15	31	NCT02424851	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials49

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38977911	RESULT	1	PubMed
22946986	RESULT	1	PubMed
18382267	RESULT	1	PubMed
15233820	RESULT	1	PubMed
12176628	RESULT	1	PubMed
12176626	RESULT	1	PubMed
41667648	DERIVED	1	PubMed
41551843	DERIVED	1	PubMed
41500624	DERIVED	1	PubMed
41428405	DERIVED	1	PubMed

1 to 10 of 49

See all 49 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001106

GET https://conductscience.org/api/diseases/v1/MONDO_0001106/drugs?page=2

API reference For AI assistants